CJC-1295 with DAC 5mg
GHRH analog with drug-affinity complex. Extended-half-life GH-axis research peptide.
GHRH analog with drug-affinity complex. Extended-half-life GH-axis research peptide.
The primary literature on this compound includes Teichman et al., J Clin Endocrinol Metab (2006). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman SL, et al. J Clin Endocrinol Metab. 2006.PubMed →
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogIonescu M, et al. J Clin Endocrinol Metab. 2006.PubMed →
Further reading in the lab library
Researchers also ordered
- CJC-1295 (no DAC)Modified GHRH (1-29) analog without drug-affinity complex. Short half-life GH-axis research peptide.
- GHRP-2Synthetic hexapeptide ghrelin mimetic. GHSR-1a agonist studied in growth-hormone-release research.
- GHRP-6Hexapeptide ghrelin mimetic with appetite-research activity. GHSR-1a agonist.
- IGF-1 LR3 1mgLong Arg3 IGF-1 — research-volume vial.